PHAP I (Intermediate Domain) Blocking Peptide
| Code | Size | Price |
|---|
| LEI-P220-50ug | 50 ug | £216.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.2 mg/ml
Format:
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Formulation:
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Long Description:
PHAP I peptide is applicable as a control peptide for blocking antibody binding in Western blotting.
Target:
PHAP I
References
1. Crook NE, Clem RJ, and Miller LK. An apoptosis inhibiting baculovirus gene with a zinc finger like motif. J. Virol. 1993; 67:2168-2174.
2. Liston P, Fong WG, and Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22:8568-80.
3. Vaux DL and Silke J. Mammalian mitochondrial IAP binding proteins. Biochem. Biophys. Res. Comm. 2003; 304:499-504.
4. Suzuki Y, Imai Y, Nakayama H, et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 2001; 8:613-21.
Related Products
| Product Name | Product Code | Supplier | Anti-Human PHAP I (CT) | LEI-P209 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human PHAP I (Intermediate Domain) | LEI-P210 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHAP I (CT) Blocking Peptide | LEI-P219 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||